Cell Viability Assays Market by Product (MTT Assay, XTT Assay, Calcein, Resazurin, Flow Cytometry, Spectrophotometer), Cell Type (Human, Animal, Microbial), Application (Basic Research, Stem Cell, Discovery & Development) - Global Forecast to 2023
“The global cell viability assays market is projected to grow at a CAGR of 8.4%.”
The cell viability assays market is expected to reach USD 4.16 billion by 2023 from an estimated USD 2.78 billion in 2018, at a CAGR of 8.4%. The rising incidence and prevalence of chronic and infectious diseases, growing availability of funds for research and rising demand for cell-based assays in research, and increasing focus on the development of cell-based therapeutics are the key drivers for market growth. However, the high cost of instruments is expected to restrain the growth of this market to a certain extent during the forecast period.
“The human cells segment to witness the highest growth during the forecast period.”
On the basis of cell type, the cell viability assays market is segmented into human cells, animal cells, and microbial cells. The human cells segment is expected to register the highest CAGR during the forecast period. Growth in this segment is mainly due to the growing investments by government bodies and private sector organizations in research activities that are focused on developing new treatments for various human diseases.
“The stem cell research applications segment to witness the highest growth during the forecast period.”
On the basis of application, the cell viability assays market is segmented into drug discovery & development, basic research, stem cell research, clinical & diagnostic applications, and other applications. The stem cell research applications segment is expected to witness the highest CAGR owing to the increasing number of stem cell research activities and rising investments in stem cell research.
“APAC is projected to witness the highest growth during the forecast period.”
North America is expected to account for the largest share of the global cell viability assays market in 2018. On the other hand, the APAC region is expected to witness the highest CAGR during the forecast period, owing to the increasing prevalence of chronic and infectious diseases in this region, large patient population, increasing healthcare spending, and growing interest of key players in APAC countries.
The breakdown of primary participants was as mentioned below:
Research Coverage:
The report analyzes the various cell viability products and their adoption pattern. It aims at estimating the market size and future growth potential of the global cell viability assays market for different segments such as products, cell types, applications, end users, and regions. The report also includes an in-depth competitive analysis of the key players in this market along with their company profiles, product offerings, and recent developments.
Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies for strengthening the market.
This report provides insights on the following pointers:
The cell viability assays market is expected to reach USD 4.16 billion by 2023 from an estimated USD 2.78 billion in 2018, at a CAGR of 8.4%. The rising incidence and prevalence of chronic and infectious diseases, growing availability of funds for research and rising demand for cell-based assays in research, and increasing focus on the development of cell-based therapeutics are the key drivers for market growth. However, the high cost of instruments is expected to restrain the growth of this market to a certain extent during the forecast period.
“The human cells segment to witness the highest growth during the forecast period.”
On the basis of cell type, the cell viability assays market is segmented into human cells, animal cells, and microbial cells. The human cells segment is expected to register the highest CAGR during the forecast period. Growth in this segment is mainly due to the growing investments by government bodies and private sector organizations in research activities that are focused on developing new treatments for various human diseases.
“The stem cell research applications segment to witness the highest growth during the forecast period.”
On the basis of application, the cell viability assays market is segmented into drug discovery & development, basic research, stem cell research, clinical & diagnostic applications, and other applications. The stem cell research applications segment is expected to witness the highest CAGR owing to the increasing number of stem cell research activities and rising investments in stem cell research.
“APAC is projected to witness the highest growth during the forecast period.”
North America is expected to account for the largest share of the global cell viability assays market in 2018. On the other hand, the APAC region is expected to witness the highest CAGR during the forecast period, owing to the increasing prevalence of chronic and infectious diseases in this region, large patient population, increasing healthcare spending, and growing interest of key players in APAC countries.
The breakdown of primary participants was as mentioned below:
- By Company Type: Tier 1–45%, Tier 2–40%, and Tier 3–15%
- By Designation: C-level–43%, Director Level–30%, and Others–27%
- By Region: North America–32%, Europe–27%, Asia Pacific–19%, and RoW–22%
Research Coverage:
The report analyzes the various cell viability products and their adoption pattern. It aims at estimating the market size and future growth potential of the global cell viability assays market for different segments such as products, cell types, applications, end users, and regions. The report also includes an in-depth competitive analysis of the key players in this market along with their company profiles, product offerings, and recent developments.
Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies for strengthening the market.
This report provides insights on the following pointers:
- Market Penetration: Comprehensive information on the product portfolios offered by the top players in the global cell viability assays market
- Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the global cell viability assays market
- Market Development: Comprehensive information on the lucrative emerging regions by product, cell type, application, end user, and region
- Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the global cell viability assays market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and products of leading players in the global cell viability assays market
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY SOURCES
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.2 MARKET SIZE ESTIMATION
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 MARKET SHARE ESTIMATION
2.5 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 CELL VIABILITY ASSAYS MARKET OVERVIEW
4.2 CELL VIABILITY ASSAYS MARKET: GEOGRAPHIC OVERVIEW (2017)
4.3 REGIONAL MIX: CELL VIABILITY ASSAYS MARKET (2018–2023)
4.4 ASIA PACIFIC: CELL VIABILITY ASSAYS MARKET, BY END USER & COUNTRY (2017)
4.5 CELL VIABILITY ASSAYS MARKET: DEVELOPED VS. DEVELOPING MARKETS
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Rising incidence and prevalence of chronic and infectious diseases
5.2.1.2 Growing availability of funds for research
5.2.1.3 Rising demand for cell-based assays in research
5.2.1.4 Increasing focus on the development of cell-based therapeutics
5.2.2 RESTRAINT
5.2.2.1 High cost of instruments
5.2.3 OPPORTUNITIES
5.2.3.1 Emerging markets
5.2.3.2 Growing focus on stem cell research
6 CELL VIABILITY ASSAYS MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 CONSUMABLES
6.2.1 REAGENTS
6.2.2 ASSAY KITS
6.2.2.1 Tetrazolium reduction assay kits
6.2.2.1.1 MTT assay kits
6.2.2.1.2 Other tetrazolium assay kits
6.2.2.2 Resazurin cell viability assay kits
6.2.2.3 Calcein-AM cell viability assay kits
6.2.2.4 Other assay kits
6.2.3 MICROPLATES
6.3 INSTRUMENTS
6.3.1 AUTOMATED CELL COUNTERS
6.3.2 FLOW CYTOMETERS
6.3.3 SPECTROPHOTOMETERS
6.3.4 CELL IMAGING & ANALYSIS SYSTEMS
7 CELL VIABILITY ASSAYS MARKET, BY CELL TYPE
7.1 INTRODUCTION
7.2 HUMAN CELLS
7.3 ANIMAL CELLS
7.4 MICROBIAL CELLS
8 CELL VIABILITY ASSAYS MARKET, BY APPLICATION
8.1 INTRODUCTION
8.2 DRUG DISCOVERY AND DEVELOPMENT
8.3 BASIC RESEARCH
8.4 STEM CELL RESEARCH
8.5 CLINICAL AND DIAGNOSTIC APPLICATIONS
8.6 OTHER APPLICATIONS
9 CELL VIABILITY ASSAYS MARKET, BY END USER
9.1 INTRODUCTION
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.3 ACADEMIC & RESEARCH INSTITUTES
9.4 HOSPITAL & DIAGNOSTIC LABORATORIES
9.5 OTHER END USERS
10 CELL VIABILITY ASSAYS MARKET, BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 US
10.2.2 CANADA
10.3 EUROPE
10.3.1 GERMANY
10.3.2 FRANCE
10.3.3 UK
10.3.4 ITALY
10.3.5 SPAIN
10.3.6 REST OF EUROPE
10.4 ASIA PACIFIC
10.4.1 JAPAN
10.4.2 CHINA
10.4.3 INDIA
10.4.4 REST OF ASIA PACIFIC
10.5 LATIN AMERICA
10.6 MIDDLE EAST & AFRICA
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 MARKET SHARE ANALYSIS
11.2.1 MARKET SHARE ANALYSIS: CELL VIABILITY ASSAY KITS MARKET
11.3 COMPETITIVE SITUATION AND TRENDS
11.3.1 PRODUCT LAUNCHES
11.3.2 EXPANSIONS
11.3.3 ACQUISITIONS
11.3.4 OTHER STRATEGIES
12 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
12.1 THERMO FISHER SCIENTIFIC
12.2 MERCK KGAA
12.3 BIO-RAD LABORATORIES
12.4 GE HEALTHCARE
12.5 DANAHER CORPORATION
12.6 BECTON, DICKINSON AND COMPANY
12.7 PROMEGA CORPORATION
12.8 BIOTIUM
12.9 ABCAM PLC
12.10 CREATIVE BIOARRAY
12.11 BIOTEK INSTRUMENTS
12.12 PERKINELMER
*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.
13 APPENDIX
13.1 INSIGHTS OF INDUSTRY EXPERTS
13.2 DISCUSSION GUIDE
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.4 AVAILABLE CUSTOMIZATIONS
13.5 RELATED REPORTS
13.6 AUTHOR DETAILS
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY SOURCES
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.2 MARKET SIZE ESTIMATION
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 MARKET SHARE ESTIMATION
2.5 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 CELL VIABILITY ASSAYS MARKET OVERVIEW
4.2 CELL VIABILITY ASSAYS MARKET: GEOGRAPHIC OVERVIEW (2017)
4.3 REGIONAL MIX: CELL VIABILITY ASSAYS MARKET (2018–2023)
4.4 ASIA PACIFIC: CELL VIABILITY ASSAYS MARKET, BY END USER & COUNTRY (2017)
4.5 CELL VIABILITY ASSAYS MARKET: DEVELOPED VS. DEVELOPING MARKETS
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Rising incidence and prevalence of chronic and infectious diseases
5.2.1.2 Growing availability of funds for research
5.2.1.3 Rising demand for cell-based assays in research
5.2.1.4 Increasing focus on the development of cell-based therapeutics
5.2.2 RESTRAINT
5.2.2.1 High cost of instruments
5.2.3 OPPORTUNITIES
5.2.3.1 Emerging markets
5.2.3.2 Growing focus on stem cell research
6 CELL VIABILITY ASSAYS MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 CONSUMABLES
6.2.1 REAGENTS
6.2.2 ASSAY KITS
6.2.2.1 Tetrazolium reduction assay kits
6.2.2.1.1 MTT assay kits
6.2.2.1.2 Other tetrazolium assay kits
6.2.2.2 Resazurin cell viability assay kits
6.2.2.3 Calcein-AM cell viability assay kits
6.2.2.4 Other assay kits
6.2.3 MICROPLATES
6.3 INSTRUMENTS
6.3.1 AUTOMATED CELL COUNTERS
6.3.2 FLOW CYTOMETERS
6.3.3 SPECTROPHOTOMETERS
6.3.4 CELL IMAGING & ANALYSIS SYSTEMS
7 CELL VIABILITY ASSAYS MARKET, BY CELL TYPE
7.1 INTRODUCTION
7.2 HUMAN CELLS
7.3 ANIMAL CELLS
7.4 MICROBIAL CELLS
8 CELL VIABILITY ASSAYS MARKET, BY APPLICATION
8.1 INTRODUCTION
8.2 DRUG DISCOVERY AND DEVELOPMENT
8.3 BASIC RESEARCH
8.4 STEM CELL RESEARCH
8.5 CLINICAL AND DIAGNOSTIC APPLICATIONS
8.6 OTHER APPLICATIONS
9 CELL VIABILITY ASSAYS MARKET, BY END USER
9.1 INTRODUCTION
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.3 ACADEMIC & RESEARCH INSTITUTES
9.4 HOSPITAL & DIAGNOSTIC LABORATORIES
9.5 OTHER END USERS
10 CELL VIABILITY ASSAYS MARKET, BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 US
10.2.2 CANADA
10.3 EUROPE
10.3.1 GERMANY
10.3.2 FRANCE
10.3.3 UK
10.3.4 ITALY
10.3.5 SPAIN
10.3.6 REST OF EUROPE
10.4 ASIA PACIFIC
10.4.1 JAPAN
10.4.2 CHINA
10.4.3 INDIA
10.4.4 REST OF ASIA PACIFIC
10.5 LATIN AMERICA
10.6 MIDDLE EAST & AFRICA
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 MARKET SHARE ANALYSIS
11.2.1 MARKET SHARE ANALYSIS: CELL VIABILITY ASSAY KITS MARKET
11.3 COMPETITIVE SITUATION AND TRENDS
11.3.1 PRODUCT LAUNCHES
11.3.2 EXPANSIONS
11.3.3 ACQUISITIONS
11.3.4 OTHER STRATEGIES
12 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
12.1 THERMO FISHER SCIENTIFIC
12.2 MERCK KGAA
12.3 BIO-RAD LABORATORIES
12.4 GE HEALTHCARE
12.5 DANAHER CORPORATION
12.6 BECTON, DICKINSON AND COMPANY
12.7 PROMEGA CORPORATION
12.8 BIOTIUM
12.9 ABCAM PLC
12.10 CREATIVE BIOARRAY
12.11 BIOTEK INSTRUMENTS
12.12 PERKINELMER
*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.
13 APPENDIX
13.1 INSIGHTS OF INDUSTRY EXPERTS
13.2 DISCUSSION GUIDE
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.4 AVAILABLE CUSTOMIZATIONS
13.5 RELATED REPORTS
13.6 AUTHOR DETAILS
LIST OF TABLES
Table 1 CELL VIABILITY ASSAYS MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, AND OPPORTUNITIES
Table 2 INCREASE IN CANCER PATIENT POPULATION, BY CANCER TYPE
Table 3 CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 4 CELL VIABILITY ASSAYS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 5 CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 6 CELL VIABILITY CONSUMABLES MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 7 CELL VIABILITY REAGENTS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 8 CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 9 CELL VIABILITY ASSAY KITS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 10 CELL VIABILITY ASSAY KITS OFFERED BY PROMINENT PLAYERS
Table 11 TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 12 TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 13 MTT ASSAY KITS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 14 OTHER TETRAZOLIUM ASSAY KITS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 15 RESAZURIN CELL VIABILITY ASSAY KITS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 16 CALCEIN-AM CELL VIABILITY ASSAY KITS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 17 OTHER ASSAY KITS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 18 CELL VIABILITY MICROPLATES MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 19 CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 20 CELL VIABILITY INSTRUMENTS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 21 AUTOMATED CELL COUNTERS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 22 FLOW CYTOMETERS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 23 SPECTROPHOTOMETERS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 24 CELL IMAGING & ANALYSIS SYSTEMS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 25 CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016–2023 (USD MILLION)
Table 26 CELL VIABILITY ASSAYS MARKET FOR HUMAN CELLS, BY COUNTRY/REGION, 2016–2023 (USD MILLION)
Table 27 CELL VIABILITY ASSAYS MARKET FOR ANIMAL CELLS, BY COUNTRY/REGION, 2016–2023 (USD MILLION)
Table 28 CELL VIABILITY ASSAYS MARKET FOR MICROBIAL CELLS, BY COUNTRY/REGION, 2016–2023 (USD MILLION)
Table 29 CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 30 CELL VIABILITY ASSAYS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY COUNTRY, 2016–2023 (USD MILLION)
Table 31 CELL VIABILITY ASSAYS MARKET FOR BASIC RESEARCH, BY COUNTRY, 2016–2023 (USD MILLION)
Table 32 CELL VIABILITY ASSAYS MARKET FOR STEM CELL RESEARCH, BY COUNTRY, 2016–2023 (USD MILLION)
Table 33 CELL VIABILITY ASSAYS MARKET FOR CLINICAL AND DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2016–2023 (USD MILLION)
Table 34 CELL VIABILITY ASSAYS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2016–2023 (USD MILLION)
Table 35 CELL VIABILITY ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 36 CELL VIABILITY ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2016–2023 (USD MILLION)
Table 37 CELL VIABILITY ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2016–2023 (USD MILLION)
Table 38 CELL VIABILITY ASSAYS MARKET FOR HOSPITAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2016–2023 (USD MILLION)
Table 39 CELL VIABILITY ASSAYS MARKET FOR OTHER END USERS, BY COUNTRY, 2016–2023 (USD MILLION)
Table 40 CELL VIABILITY ASSAYS MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 41 NORTH AMERICA: CELL VIABILITY ASSAYS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 42 NORTH AMERICA: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 43 NORTH AMERICA: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 44 NORTH AMERICA: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 45 NORTH AMERICA: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 46 NORTH AMERICA: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 47 NORTH AMERICA: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016–2023 (USD MILLION)
Table 48 NORTH AMERICA: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 49 NORTH AMERICA: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 50 US: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 51 US: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 52 US: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 53 US: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 54 US: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 55 US: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016–2023 (USD MILLION)
Table 56 US: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 57 US: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 58 CANADA: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 59 CANADA: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 60 CANADA: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 61 CANADA: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 62 CANADA: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 63 CANADA: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016–2023 (USD MILLION)
Table 64 CANADA: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 65 CANADA: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 66 EUROPE: CELL VIABILITY ASSAYS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 67 EUROPE: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 68 EUROPE: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 69 EUROPE: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 70 EUROPE: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 71 EUROPE: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 72 EUROPE: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016–2023 (USD MILLION)
Table 73 EUROPE: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 74 EUROPE: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 75 GERMANY: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 76 GERMANY: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 77 GERMANY: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 78 GERMANY: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 79 GERMANY: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 80 GERMANY: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016–2023 (USD MILLION)
Table 81 GERMANY: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 82 GERMANY: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 83 FRANCE: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 84 FRANCE: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 85 FRANCE: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 86 FRANCE: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 87 FRANCE: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 88 FRANCE: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016–2023 (USD MILLION)
Table 89 FRANCE: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 90 FRANCE: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 91 UK: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 92 UK: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 93 UK: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 94 UK: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 95 UK: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 96 UK: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016–2023 (USD MILLION)
Table 97 UK: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 98 UK: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 99 ITALY: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 100 ITALY: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 101 ITALY: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 102 ITALY: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 103 ITALY: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 104 ITALY: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016–2023 (USD MILLION)
Table 105 ITALY: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 106 ITALY: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 107 SPAIN: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 108 SPAIN: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 109 SPAIN: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 110 SPAIN: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 111 SPAIN: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 112 SPAIN: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016–2023 (USD MILLION)
Table 113 SPAIN: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 114 SPAIN: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 115 ROE: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 116 ROE: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 117 ROE: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 118 ROE: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 119 ROE: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 120 ROE: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016–2023 (USD MILLION)
Table 121 ROE: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 122 ROE: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 123 ASIA PACIFIC: CELL VIABILITY ASSAYS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 124 ASIA PACIFIC: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 125 ASIA PACIFIC: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 126 ASIA PACIFIC: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 127 ASIA PACIFIC: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 128 ASIA PACIFIC: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 129 ASIA PACIFIC: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016–2023 (USD MILLION)
Table 130 ASIA PACIFIC: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 131 ASIA PACIFIC: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 132 JAPAN: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 133 JAPAN: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 134 JAPAN: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 135 JAPAN: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 136 JAPAN: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 137 JAPAN: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016–2023 (USD MILLION)
Table 138 JAPAN: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 139 JAPAN: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 140 CHINA: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 141 CHINA: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 142 CHINA: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 143 CHINA: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 144 CHINA: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 145 CHINA: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016–2023 (USD MILLION)
Table 146 CHINA: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 147 CHINA: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 148 INDIA: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 149 INDIA: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 150 INDIA: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 151 INDIA: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 152 INDIA: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 153 INDIA: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016–2023 (USD MILLION)
Table 154 INDIA: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 155 INDIA: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 156 ROAPAC: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 157 ROAPAC: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 158 ROAPAC: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 159 ROAPAC: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 160 ROAPAC: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 161 ROAPAC: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016–2023 (USD MILLION)
Table 162 ROAPAC: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 163 ROAPAC: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 164 LATIN AMERICA: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 165 LATIN AMERICA: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 166 LATIN AMERICA: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 167 LATIN AMERICA: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 168 LATIN AMERICA: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 169 LATIN AMERICA: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016–2023 (USD MILLION)
Table 170 LATIN AMERICA: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 171 LATIN AMERICA: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 172 MIDDLE EAST & AFRICA: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 173 MIDDLE EAST & AFRICA: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 174 MIDDLE EAST & AFRICA: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 175 MIDDLE EAST & AFRICA: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 176 MIDDLE EAST & AFRICA: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 177 MIDDLE EAST & AFRICA: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016–2023 (USD MILLION)
Table 178 MIDDLE EAST & AFRICA: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 179 MIDDLE EAST & AFRICA: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 180 GROWTH STRATEGY MATRIX (2015–2018)
Table 181 PRODUCT LAUNCHES, 2015–2018
Table 182 EXPANSIONS, 2015–2018
Table 183 ACQUISITIONS, 2015–2018
Table 184 OTHER STRATEGIES, 2015–2018
Table 1 CELL VIABILITY ASSAYS MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, AND OPPORTUNITIES
Table 2 INCREASE IN CANCER PATIENT POPULATION, BY CANCER TYPE
Table 3 CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 4 CELL VIABILITY ASSAYS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 5 CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 6 CELL VIABILITY CONSUMABLES MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 7 CELL VIABILITY REAGENTS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 8 CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 9 CELL VIABILITY ASSAY KITS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 10 CELL VIABILITY ASSAY KITS OFFERED BY PROMINENT PLAYERS
Table 11 TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 12 TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 13 MTT ASSAY KITS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 14 OTHER TETRAZOLIUM ASSAY KITS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 15 RESAZURIN CELL VIABILITY ASSAY KITS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 16 CALCEIN-AM CELL VIABILITY ASSAY KITS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 17 OTHER ASSAY KITS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 18 CELL VIABILITY MICROPLATES MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 19 CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 20 CELL VIABILITY INSTRUMENTS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 21 AUTOMATED CELL COUNTERS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 22 FLOW CYTOMETERS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 23 SPECTROPHOTOMETERS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 24 CELL IMAGING & ANALYSIS SYSTEMS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 25 CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016–2023 (USD MILLION)
Table 26 CELL VIABILITY ASSAYS MARKET FOR HUMAN CELLS, BY COUNTRY/REGION, 2016–2023 (USD MILLION)
Table 27 CELL VIABILITY ASSAYS MARKET FOR ANIMAL CELLS, BY COUNTRY/REGION, 2016–2023 (USD MILLION)
Table 28 CELL VIABILITY ASSAYS MARKET FOR MICROBIAL CELLS, BY COUNTRY/REGION, 2016–2023 (USD MILLION)
Table 29 CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 30 CELL VIABILITY ASSAYS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY COUNTRY, 2016–2023 (USD MILLION)
Table 31 CELL VIABILITY ASSAYS MARKET FOR BASIC RESEARCH, BY COUNTRY, 2016–2023 (USD MILLION)
Table 32 CELL VIABILITY ASSAYS MARKET FOR STEM CELL RESEARCH, BY COUNTRY, 2016–2023 (USD MILLION)
Table 33 CELL VIABILITY ASSAYS MARKET FOR CLINICAL AND DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2016–2023 (USD MILLION)
Table 34 CELL VIABILITY ASSAYS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2016–2023 (USD MILLION)
Table 35 CELL VIABILITY ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 36 CELL VIABILITY ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2016–2023 (USD MILLION)
Table 37 CELL VIABILITY ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2016–2023 (USD MILLION)
Table 38 CELL VIABILITY ASSAYS MARKET FOR HOSPITAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2016–2023 (USD MILLION)
Table 39 CELL VIABILITY ASSAYS MARKET FOR OTHER END USERS, BY COUNTRY, 2016–2023 (USD MILLION)
Table 40 CELL VIABILITY ASSAYS MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 41 NORTH AMERICA: CELL VIABILITY ASSAYS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 42 NORTH AMERICA: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 43 NORTH AMERICA: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 44 NORTH AMERICA: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 45 NORTH AMERICA: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 46 NORTH AMERICA: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 47 NORTH AMERICA: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016–2023 (USD MILLION)
Table 48 NORTH AMERICA: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 49 NORTH AMERICA: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 50 US: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 51 US: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 52 US: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 53 US: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 54 US: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 55 US: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016–2023 (USD MILLION)
Table 56 US: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 57 US: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 58 CANADA: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 59 CANADA: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 60 CANADA: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 61 CANADA: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 62 CANADA: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 63 CANADA: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016–2023 (USD MILLION)
Table 64 CANADA: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 65 CANADA: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 66 EUROPE: CELL VIABILITY ASSAYS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 67 EUROPE: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 68 EUROPE: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 69 EUROPE: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 70 EUROPE: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 71 EUROPE: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 72 EUROPE: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016–2023 (USD MILLION)
Table 73 EUROPE: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 74 EUROPE: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 75 GERMANY: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 76 GERMANY: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 77 GERMANY: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 78 GERMANY: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 79 GERMANY: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 80 GERMANY: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016–2023 (USD MILLION)
Table 81 GERMANY: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 82 GERMANY: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 83 FRANCE: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 84 FRANCE: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 85 FRANCE: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 86 FRANCE: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 87 FRANCE: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 88 FRANCE: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016–2023 (USD MILLION)
Table 89 FRANCE: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 90 FRANCE: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 91 UK: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 92 UK: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 93 UK: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 94 UK: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 95 UK: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 96 UK: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016–2023 (USD MILLION)
Table 97 UK: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 98 UK: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 99 ITALY: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 100 ITALY: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 101 ITALY: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 102 ITALY: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 103 ITALY: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 104 ITALY: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016–2023 (USD MILLION)
Table 105 ITALY: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 106 ITALY: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 107 SPAIN: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 108 SPAIN: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 109 SPAIN: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 110 SPAIN: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 111 SPAIN: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 112 SPAIN: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016–2023 (USD MILLION)
Table 113 SPAIN: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 114 SPAIN: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 115 ROE: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 116 ROE: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 117 ROE: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 118 ROE: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 119 ROE: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 120 ROE: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016–2023 (USD MILLION)
Table 121 ROE: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 122 ROE: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 123 ASIA PACIFIC: CELL VIABILITY ASSAYS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 124 ASIA PACIFIC: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 125 ASIA PACIFIC: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 126 ASIA PACIFIC: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 127 ASIA PACIFIC: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 128 ASIA PACIFIC: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 129 ASIA PACIFIC: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016–2023 (USD MILLION)
Table 130 ASIA PACIFIC: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 131 ASIA PACIFIC: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 132 JAPAN: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 133 JAPAN: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 134 JAPAN: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 135 JAPAN: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 136 JAPAN: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 137 JAPAN: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016–2023 (USD MILLION)
Table 138 JAPAN: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 139 JAPAN: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 140 CHINA: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 141 CHINA: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 142 CHINA: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 143 CHINA: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 144 CHINA: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 145 CHINA: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016–2023 (USD MILLION)
Table 146 CHINA: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 147 CHINA: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 148 INDIA: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 149 INDIA: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 150 INDIA: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 151 INDIA: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 152 INDIA: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 153 INDIA: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016–2023 (USD MILLION)
Table 154 INDIA: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 155 INDIA: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 156 ROAPAC: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 157 ROAPAC: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 158 ROAPAC: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 159 ROAPAC: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 160 ROAPAC: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 161 ROAPAC: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016–2023 (USD MILLION)
Table 162 ROAPAC: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 163 ROAPAC: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 164 LATIN AMERICA: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 165 LATIN AMERICA: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 166 LATIN AMERICA: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 167 LATIN AMERICA: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 168 LATIN AMERICA: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 169 LATIN AMERICA: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016–2023 (USD MILLION)
Table 170 LATIN AMERICA: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 171 LATIN AMERICA: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 172 MIDDLE EAST & AFRICA: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 173 MIDDLE EAST & AFRICA: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 174 MIDDLE EAST & AFRICA: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 175 MIDDLE EAST & AFRICA: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 176 MIDDLE EAST & AFRICA: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 177 MIDDLE EAST & AFRICA: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016–2023 (USD MILLION)
Table 178 MIDDLE EAST & AFRICA: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 179 MIDDLE EAST & AFRICA: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 180 GROWTH STRATEGY MATRIX (2015–2018)
Table 181 PRODUCT LAUNCHES, 2015–2018
Table 182 EXPANSIONS, 2015–2018
Table 183 ACQUISITIONS, 2015–2018
Table 184 OTHER STRATEGIES, 2015–2018
LIST OF FIGURES
Figure 1 RESEARCH DESIGN
Figure 2 PRIMARY SOURCES
Figure 3 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
Figure 4 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION
Figure 5 BOTTOM-UP APPROACH
Figure 6 TOP-DOWN APPROACH
Figure 7 DATA TRIANGULATION METHODOLOGY
Figure 8 CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2018 VS. 2023 (USD MILLION)
Figure 9 CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2018 VS. 2023 (USD MILLION)
Figure 10 CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2018 VS. 2023 (USD MILLION)
Figure 11 CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2018 VS. 2023 (USD MILLION)
Figure 12 CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2018 VS. 2023 (USD MILLION)
Figure 13 CELL VIABILITY ASSAYS MARKET, BY END USER, 2018 VS. 2023 (USD MILLION)
Figure 14 GEOGRAPHICAL SNAPSHOT OF THE CELL VIABILITY ASSAYS MARKET
Figure 15 RISING INCIDENCE AND PREVALENCE OF CHRONIC AND INFECTIOUS DISEASES IS EXPECTED TO DRIVE MARKET GROWTH
Figure 16 THE US HELD THE LARGEST SHARE OF THE MARKET IN 2017
Figure 17 APAC TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD (2018–2023)
Figure 18 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES ACCOUNTED FOR THE LARGEST SHARE OF THE APAC CELL VIABILITY ASSAYS MARKET IN 2017
Figure 19 DEVELOPING MARKETS TO REGISTER A HIGHER GROWTH RATE DURING THE FORECAST PERIOD
Figure 20 REAGENTS TO DOMINATE THE CELL VIABILITY CONSUMABLES MARKET DURING THE FORECAST PERIOD
Figure 21 AUTOMATED CELL COUNTERS TO DOMINATE THE CELL VIABILITY INSTRUMENTS MARKET DURING THE FORECAST PERIOD
Figure 22 HUMAN CELLS SEGMENT TO WITNESS THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD (2018–2023)
Figure 23 DRUG DISCOVERY AND DEVELOPMENT ESTIMATED TO BE THE LARGEST APPLICATION OF CELL VIABILITY ASSAYS IN 2018
Figure 24 CELL VIABILITY ASSAYS MARKET, BY END USER, 2018 VS. 2023 (USD MILLION)
Figure 25 CELL VIABILITY ASSAYS MARKET: GEOGRAPHIC SNAPSHOT (2017)
Figure 26 NORTH AMERICA: CELL VIABILITY ASSAYS MARKET SNAPSHOT
Figure 27 NIH FUNDING ON STEM CELL RESEARCH, 2013–2016 (USD BILLION)
Figure 28 EUROPE: CELL VIABILITY ASSAYS MARKET SNAPSHOT
Figure 29 ASIA PACIFIC: CELL VIABILITY ASSAYS MARKET SNAPSHOT
Figure 30 PRODUCT LAUNCHES—KEY GROWTH STRATEGY ADOPTED BY MARKET PLAYERS FROM 2015 TO MAY 2018
Figure 31 CELL VIABILITY ASSAY KITS MARKET, BY KEY PLAYER, 2017
Figure 32 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2017)
Figure 33 MERCK KGAA: COMPANY SNAPSHOT (2017)
Figure 34 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2017)
Figure 35 GE HEALTHCARE: COMPANY SNAPSHOT (2017)
Figure 36 DANAHER CORPORATION: COMPANY SNAPSHOT (2017)
Figure 37 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2017)
Figure 38 ABCAM PLC: COMPANY SNAPSHOT (2017)
Figure 39 PERKINELMER: COMPANY SNAPSHOT (2017)
Figure 1 RESEARCH DESIGN
Figure 2 PRIMARY SOURCES
Figure 3 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
Figure 4 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION
Figure 5 BOTTOM-UP APPROACH
Figure 6 TOP-DOWN APPROACH
Figure 7 DATA TRIANGULATION METHODOLOGY
Figure 8 CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2018 VS. 2023 (USD MILLION)
Figure 9 CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2018 VS. 2023 (USD MILLION)
Figure 10 CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2018 VS. 2023 (USD MILLION)
Figure 11 CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2018 VS. 2023 (USD MILLION)
Figure 12 CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2018 VS. 2023 (USD MILLION)
Figure 13 CELL VIABILITY ASSAYS MARKET, BY END USER, 2018 VS. 2023 (USD MILLION)
Figure 14 GEOGRAPHICAL SNAPSHOT OF THE CELL VIABILITY ASSAYS MARKET
Figure 15 RISING INCIDENCE AND PREVALENCE OF CHRONIC AND INFECTIOUS DISEASES IS EXPECTED TO DRIVE MARKET GROWTH
Figure 16 THE US HELD THE LARGEST SHARE OF THE MARKET IN 2017
Figure 17 APAC TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD (2018–2023)
Figure 18 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES ACCOUNTED FOR THE LARGEST SHARE OF THE APAC CELL VIABILITY ASSAYS MARKET IN 2017
Figure 19 DEVELOPING MARKETS TO REGISTER A HIGHER GROWTH RATE DURING THE FORECAST PERIOD
Figure 20 REAGENTS TO DOMINATE THE CELL VIABILITY CONSUMABLES MARKET DURING THE FORECAST PERIOD
Figure 21 AUTOMATED CELL COUNTERS TO DOMINATE THE CELL VIABILITY INSTRUMENTS MARKET DURING THE FORECAST PERIOD
Figure 22 HUMAN CELLS SEGMENT TO WITNESS THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD (2018–2023)
Figure 23 DRUG DISCOVERY AND DEVELOPMENT ESTIMATED TO BE THE LARGEST APPLICATION OF CELL VIABILITY ASSAYS IN 2018
Figure 24 CELL VIABILITY ASSAYS MARKET, BY END USER, 2018 VS. 2023 (USD MILLION)
Figure 25 CELL VIABILITY ASSAYS MARKET: GEOGRAPHIC SNAPSHOT (2017)
Figure 26 NORTH AMERICA: CELL VIABILITY ASSAYS MARKET SNAPSHOT
Figure 27 NIH FUNDING ON STEM CELL RESEARCH, 2013–2016 (USD BILLION)
Figure 28 EUROPE: CELL VIABILITY ASSAYS MARKET SNAPSHOT
Figure 29 ASIA PACIFIC: CELL VIABILITY ASSAYS MARKET SNAPSHOT
Figure 30 PRODUCT LAUNCHES—KEY GROWTH STRATEGY ADOPTED BY MARKET PLAYERS FROM 2015 TO MAY 2018
Figure 31 CELL VIABILITY ASSAY KITS MARKET, BY KEY PLAYER, 2017
Figure 32 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2017)
Figure 33 MERCK KGAA: COMPANY SNAPSHOT (2017)
Figure 34 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2017)
Figure 35 GE HEALTHCARE: COMPANY SNAPSHOT (2017)
Figure 36 DANAHER CORPORATION: COMPANY SNAPSHOT (2017)
Figure 37 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2017)
Figure 38 ABCAM PLC: COMPANY SNAPSHOT (2017)
Figure 39 PERKINELMER: COMPANY SNAPSHOT (2017)
